Hikal Limited has scheduled an earnings conference call to discuss its financial and operational performance for the third quarter and nine months of FY26. The company made this announcement through a regulatory filing on February 04, 2026, in compliance with SEBI listing regulations.

Conference Call Details

The earnings call is scheduled for Wednesday, February 11, 2026, at 4:30 PM IST. The call will focus on discussing the financial and operational performance for the quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature participation from key members of Hikal Limited's senior management team:

• Mr. Sameer Hiremath - Vice Chairman and Managing Director
• Mr. Kuldeep Jain - Chief Financial Officer
• Mr. Anish Swadi - Senior President, Business Transformation and Animal Health
• Mr. Manoj Mehrotra - President, Pharmaceuticals Business
• Mr. Vimal Kulshrestha - President, Crop Protection Business

Access Information

The company has provided multiple access options for participants to join the conference call. Universal access numbers include +91 22 6280 1309 and +91 22 7115 8210 for domestic participants.

International toll-free numbers are available for global participants:

• Hong Kong: 800964448
• Singapore: 8001012045
• UK: 08081011573
• USA: 18667462133

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Rajasekhar Reddy, Company Secretary & Compliance Officer, and submitted to both BSE Limited (Scrip Code: 524735) and National Stock Exchange of India Limited (Symbol: HIKAL).

Strategic Growth Advisors Pvt. Ltd. is coordinating the conference call arrangements, with contact persons Jigar Kavaiya and Prachi Sharma available for RSVP and additional information.

Hikal Limited has disclosed significant irregularities in revenue recognition that have impacted its financial results across three quarters, following a comprehensive fact-finding review that uncovered employee misconduct involving document alterations.

Nature of Irregularities

The pharmaceutical and crop protection company identified suspected misconduct by certain employees involving irregularities and alteration of documents relating to revenue recognition. The irregularities were discovered during a fact-finding review and are being treated as misconduct by the company.

Financial Impact Assessment

The company has quantified the impact of these irregularities across the affected quarters, with the most significant adjustment being a revenue reversal of ₹80.70 crore in Q2FY26.

The impact primarily relates to revenue recognition timing, including potential reversals and adjustments to revenue recorded in the relevant periods. These adjustments have consequential impacts on quarterly financial results and related financial statement line items.

Company's Position and Clarifications

Hikal Limited has provided important clarifications regarding the nature of the irregularities and their impact on the company's operations. The company emphasized that despite the irregularities, all recognized transactions are legitimate and backed by proper documentation.

Key clarifications include:

• All underlying sales transactions are genuine and supported by customer purchase orders
• No siphoning, embezzlement, or misappropriation of company funds has occurred
• The irregularities relate specifically to timing of revenue recognition rather than fictitious sales
• The company has already taken corrective action by reversing ₹80.70 crore in Q2FY26

Regulatory Compliance and Next Steps

The company is currently evaluating applicable reporting requirements and will take appropriate steps to report the matter to relevant authorities as required under applicable laws and regulations, subject to legal advice. This disclosure has been made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Hikal stated it is assessing its statutory obligations and preparing to notify authorities where required, demonstrating the company's commitment to regulatory compliance and transparency in addressing the internal control issues.

The company has confirmed that all underlying sales are genuine, despite the revenue recognition irregularities affecting Q4FY25, Q1FY26, and Q2FY26. The most significant impact was a revenue reversal of ₹80.70 crore in Q2FY26, which has already been implemented by the company.